Evidence mapPaperPMID 36046494Full record

ReviewFrontiers in aging neuroscience2022

Statins and cognition: Modifying factors and possible underlying mechanisms.

Tahereh Jamshidnejad-Tosaramandani, Soheila Kashanian, Mohamed H Al-Sabri, Daniela Kročianová, Laura E Clemensson, Mélissa Gentreau, Helgi B Schiöth

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. The Impact of Cognitive Impairment on Cardiovascular Disease.Journal of the American College of Cardiology · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Tahereh Jamshidnejad-TosaramandaniNanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran.
Soheila KashanianNanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran.
Mohamed H Al-SabriDepartment of Surgical Science, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
Daniela KročianováDepartment of Surgical Science, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
Laura E ClemenssonDepartment of Surgical Science, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
Mélissa GentreauDepartment of Surgical Science, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
Helgi B SchiöthDepartment of Surgical Science, Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden.
Uppsala University · SERazi University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Statins are a class of widely prescribed drugs used to reduce low-density lipoprotein cholesterol (LDL-C) and important to prevent cardiovascular diseases (CVD). Most statin users are older adults with CVD, who are also at high risk of cognitive decline. It has been suggested that statins can alter cognitive performance, although their positive or negative effects are still debated. With more than 200 million people on statin therapy worldwide, it is crucial to understand the reasons behind discrepancies in the results of these studies. Here, we review the effects of statins on cognitive function and their association with different etiologies of dementia, and particularly, Alzheimer's disease (AD). First, we summarized the main individual and statin-related factors that could modify the cognitive effects of statins. Second, we proposed the underlying mechanisms for the protective and adverse effects of statins on cognitive performance. Finally, we discussed potential causes of discrepancies between studies and suggested approaches to improve future studies assessing the impact of statins on dementia risk and cognitive function.

Indexed as

Alzheimer’s diseasecognitive functionfactorsmechanismsrepurposingstatins

Identifiers

PMID36046494
PMCPMC9421063
OpenAlexW4291465177

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.